Enanta says Phase 2 trial shows zelicapavir reduces RSV symptom duration, hospitalization
PUBT · 05/04 11:00
Share
Listen to the news
- Enanta Pharmaceuticals flagged new Phase 2 data for zelicapavir in respiratory syncytial virus, with results set for presentation May 19, 2026 at American Thoracic Society International Conference.
- Trial readout showed zelicapavir shortened symptom duration, with fewer hospitalizations versus placebo.
- Separate preclinical posters scheduled for same meeting highlight EPS-3903, an oral STAT6 inhibitor that reduced Th2-driven inflammation in an asthma mouse model.
- Additional data point to lung-focused drug distribution for EPS-3903, with low drug-drug interaction potential aimed at supporting asthma development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260504237451) on May 04, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved